# A Study in Patients Suffering From Idiopathic Restless Legs Syndrome Who Responded to a Preceding, 6-month Treatment With Open-label Pramipexole Including Titration (0.125, 0.25, 0.5, 0.75 mg Orally q.n.)

> **NCT00152958** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 224 (—)

## Conditions studied

- Restless Legs Syndrome

## Interventions

- **DRUG:** Pramipexole

## Key facts

- **NCT ID:** NCT00152958
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-01
- **Primary completion:** 2005-02
- **Final completion:** —
- **Target enrollment:** 224 (—)
- **Last updated:** 2013-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00152958

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00152958, "A Study in Patients Suffering From Idiopathic Restless Legs Syndrome Who Responded to a Preceding, 6-month Treatment With Open-label Pramipexole Including Titration (0.125, 0.25, 0.5, 0.75 mg Orally q.n.)". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT00152958. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*